However, recent molecular and immunological investigations and treatments for CCA, including EGFR and FGFR inhibitors (pemigatinib/infigratinib/futibatinib), neurotrophic receptor tyrosine kinase inhibitor (entrectinib/larotrectinib), and ICIs (durvalumab, a PD-L1 inhibitor), will promote and accelerate the use of PIT in the near future. Here, EGFR is linked to cholangiocarcinoma.